Clinical trials for Rectal cancer

Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer #NCT05732831 #2022-502645-99-00

Innocuité et tolérance du TNG462 chez les patients atteints de tumeurs solides avec suppression du gène MTAP

Locally Advanced Metastatic Metastatic Castration-resistant MTAP 1 2 3 or more

Systemic Treatment-Naive

3 recruiting sites

Tango Therapeutics

Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer #NCT05503797 #2024-513578-23-00

Etude visant à évaluer l'efficacité et la sécurité du FORE8394 chez des participants atteints d'un cancer présentant des altérations du gène BRAF - Sous protocole C

Neuroendocrine tumor Locally Advanced Metastatic BRAF 1 2 3 or more

HRAS KRAS G12C KRAS non G12C NRAS Systemic Treatment-Naive

7 recruiting sites

Fore Biotherapeutics

Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05503797 #2024-513578-23-00

Etude visant à évaluer l'efficacité et la sécurité du FORE8394 chez des participants atteints d'un cancer présentant des altérations du gène BRAF - Sous protocole D

Locally Advanced Metastatic BRAF 1 2 3 or more

KRAS G12C KRAS non G12C NRAS HRAS Systemic Treatment-Naive

7 recruiting sites

Fore Biotherapeutics

Phase 2 Colon cancer Rectal cancer #NCT06425133 #2023-509761-21-00

[CARE] REGORAFENIB en association avec une chimiothérapie métronomique multimodale pour les cancers colorectaux métastatiques chimiorésistants

Adenocarcinoma Metastatic 1 2 3 or more Immunotherapy Chemotherapy Targeted therapy

Systemic Treatment-Naive

9 recruiting sites

Centre Hospitalier Universitaire de Besancon

Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05503797 #2024-513578-23-00

Etude visant à évaluer l'efficacité et la sécurité du FORE8394 chez des participants atteints d'un cancer présentant des altérations du gène BRAF - Sous protocole A

Locally Advanced Metastatic BRAF 1 2 3 or more

KRAS G12C KRAS non G12C NRAS HRAS Systemic Treatment-Naive

7 recruiting sites

Fore Biotherapeutics

Phase 2 Colon cancer Rectal cancer Anal cancer Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer #NCT06475352

[FUDOSE] Individualisation de la dose de chimiothérapie chez les patients atteints de cancers gastro-intestinaux dépourvus d'une enzyme hépatique spécifique

Locally Advanced Metastatic None Systemic Treatment-Naive

37 recruiting sites

UNICANCER

Phase 2 Colon cancer Rectal cancer #NCT05706779

[NEORAF] Étude de l'association de l'ENCORAFÉNIB et du CETUXIMAB en néoadjuvant chez des patients atteints d'un cancer localisé du côlon ou du rectum supérieur muté BRAF

Adenocarcinoma Localized BRAF None Systemic Treatment-Naive

KRAS G12C KRAS non G12C NRAS Targeted therapy

3 recruiting sites

Fédération Francophone de Cancérologie Digestive

Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer #NCT03093116 #2024-512606-25-00

[TRIDENT-1] Étude du REPOTRECTINIB (TPX-0005) chez des patients atteints de tumeurs solides avancées présentant des réarrangements ALK, ROS1 ou NTRK1-3

Groupe 6

Metastatic NTRK-1/2/3 1 2 3 or more Targeted therapy

Systemic Treatment-Naive

4 recruiting sites

Turning Point Therapeutics, Inc.

Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer #NCT03093116 #2024-512606-25-00

[TRIDENT-1] Étude du REPOTRECTINIB (TPX-0005) chez des patients atteints de tumeurs solides avancées présentant des réarrangements ALK, ROS1 ou NTRK1-3

Groupe 5

Metastatic NTRK-1/2/3 1 2 3 or more Immunotherapy Chemotherapy

Systemic Treatment-Naive Targeted therapy

4 recruiting sites

Turning Point Therapeutics, Inc.

Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT05875168 #2023-507937-14-00

Première étude chez l'humain du DS-3939a chez des participants atteints de tumeurs solides avancées

Locally Advanced Metastatic Metastatic Castration-resistant 1 2 3 or more

Systemic Treatment-Naive

6 recruiting sites

Daiichi Sankyo